Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Cytopenia 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1

Interventions

fludarabine phosphate 5fludarabine 3Busulfan 3Antilymphocyte Serum 3Whole-Body Irradiation 2Mycophenolic Acid 2Cyclophosphamide 2Clofarabine 2Alemtuzumab 2treosulfan 1thymoglobulin 1eltrombopag 1X-Rays 1Thiotepa 1Therapeutics 1Tacrolimus 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Emapalumab 1Cyclosporins 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bone Marrow Failure Disorders × Emapalumab × Clear all
NCT06430788 2025-12-17

A Study of Emapalumab for Pediatric Aplastic Anemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
35 enrolled
Classical hematology

Bone Marrow Failure Disorders, Cytopenia, Anemia, Aplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡